Hepatitis C virus infection: Looking for interferon free regimens

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Gonzalez Moreno J ^a   Payeras Cifre, A ^a  

^a HOSPITAL SON LLÀTZER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON; PROTEINASE INHIBITOR;

ANEMIA; ANTIVIRAL THERAPY; ANUS PRURITUS; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG METABOLISM; DRUG RESPONSE; DYSGEUSIA; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; OBESITY; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; CLASSIFICATION;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; PROTEASE INHIBITORS;

EID: 84877309445     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/825375     Document Type: Review

References (69)

1. Lavanchy D., Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection 2011 17 2 107 115 2-s2.0-78751621217 10.1111/j.1469-0691.2010.03432.x
2. Wise M., Bialek S., Finelli L., Bell B. P., Sorvillo F., Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008 47 4 1128 1135 2-s2.0-42249111023 10.1002/hep.22165 (Pubitemid 351547899)
3. European Paediatric Hepatitis C Virus Network, Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG: An International Journal of Obstetrics and Gynaecology 2001 108 4 371 377
4. Alter M. J., Gerety R. J., Smallwood L. A., Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. Journal of Infectious Diseases 1982 145 6 886 893 2-s2.0-0019948091 (Pubitemid 12088968)
5. Seeff L. B., Natural history of hepatitis C. American Journal of Medicine 1999 107 6 10S 15S
6. Liang T. J., Rehermann B., Seeff L. B., Hoofnagle J. H., Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine 2000 132 4 296 305 2-s2.0-0034651580 (Pubitemid 30106261)
7. Poynard T., Bedossa P., Opolon P., Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet 1997 349 9055 825 832 2-s2.0-0030933395 10.1016/S0140-6736(96)07642-8 (Pubitemid 27129209)
8. Ghany M. G., Strader D. B., Thomas D. L., Seeff L. B., Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49 4 1335 1374 2-s2.0-65449136656 10.1002/hep.22759
9. Assis D. N., Lin J. K., New phamacotherapy for hepatitis C. Clinical Pharmacology & Therapeutics 2012 92 3 294 305
10. Rosen H. R., Chronic hepatitis C infection. The New England Journal of Medicine 2011 364 25 2429 2438 10.1056/NEJMcp1006613
11. Chemello L., Cavalletto L., Bernardinello E., Guido M., Pontisso P., Alberti A., The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. Journal of Hepatology, Supplement 1995 23 supplement 2 8 12 2-s2.0-0029564107 (Pubitemid 26048737)
12. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Goncales J. F. L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine 2002 347 13 975 982 2-s2.0-0037179698 10.1056/NEJMoa020047
13. Pedicone L. D., Brass C. A., Albrecht J. K., Sulkowski M. S., McHutchison J. G., Lawitz E. J., Shiffman M. L., Muir A. J., Galler G. W., McCone J., Nyberg L. M., Lee W. M., Ghalib R. H., Schiff E. R., Galati J. S., Bacon B. R., Davis M. N., Mukhopadhyay P., Koury K., Noviello S., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England Journal of Medicine 2009 361 6 580 593 2-s2.0-68249154875 10.1056/NEJMoa0808010
14. Laguno M., Cifuentes C., Murillas J., Veloso S., Larrousse M., Payeras A., Bonet L., Vidal F., Milinkovic A., Bassa A., Villalonga C., Pérez I., Tural C., Martínez-Rebollar M., Calvo M., Blanco J. L., Martínez E., Sánchez-Tapias J. M., Gatell J. M., Mallolas J., Randomized trial comparing pegylated interferon -2b versus pegylated interferon -2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009 49 1 22 31 2-s2.0-58949099266 10.1002/hep.22598
15. Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V., Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H., Muir A. J., Sulkowski M., McHutchison J. G., Goldstein D. B., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 7262 399 401 2-s2.0-70349292099 10.1038/nature08309
16. di Martino V., Richou C., Cervoni J. P., Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011 54 3 789 800 10.1002/hep.24480
17. Lindenbach B. D., Rice C. M., Unravelling hepatitis C virus replication from genome to function. Nature 2005 436 7053 933 938 2-s2.0-23944476834 10.1038/nature04077 (Pubitemid 41191668)
18. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S. M., Gale M., Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003 300 5622 1145 1148 2-s2.0-0037687422 10.1126/science. 1082604 (Pubitemid 36583099)
19. Brenndorfer E. D., Brass A., Soderholm J., Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon- γ production. Gut 2012 61 4 589 596 10.1136/gut.2010.232116
20. Hézode C., Forestier N., Dusheiko G., Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine 2009 360 18 1839 1850 10.1056/NEJMoa0807650
21. McHutchison J. G., Everson G. T., Gordon S. C., Jacobson I. M., Sulkowski M., Kauffman R., McNair L., Alam J., Muir A. J., Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. The New England Journal of Medicine 2009 360 18 1827 1838 2-s2.0-65449152185 10.1056/NEJMoa0806104
22. Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011 364 25 2405 2416 2-s2.0-79959438789 10.1056/NEJMoa1012912
23. Sherman K. E., Flamm S. L., Afdhal N. H., Response-guided telaprevir combination treatment for hepatitis C virus infection. The New England Journal of Medicine 2011 365 11 1014 1024 10.1056/NEJMoa1014463
24. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., Focaccia R., Younossi Z., Foster G. R., Horban A., Ferenci P., Nevens F., Müllhaupt B., Pockros P., Terg R., Shouval D., Van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M., Telaprevir for retreatment of HCV infection. The New England Journal of Medicine 2011 364 25 2417 2428 2-s2.0-79959381354 10.1056/NEJMoa1013086
25. Pearlman B. L., Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. The Lancet Infectious Diseases 2012 12 9 717 728 10.1016/S1473-3099(12)70060-9
26. Kwo P. Y., Lawitz E. J., McCone J., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. The Lancet 2010 376 9742 705 716 10.1016/S0140-6736(10)60934-8
27. Poordad F., McCone J. Jr., Bacon B. R., Bruno S., Manns M. P., Sulkowski M. S., Jacobson I. M., Reddy K. R., Goodman Z. D., Boparai N., DiNubile M. J., Sniukiene V., Brass C. A., Albrecht J. K., Bronowicki J. P., Boceprevir for untreated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011 364 13 1195 1206 2-s2.0-79953173221 10.1056/NEJMoa1010494
28. Bacon B. R., Gordon S. C., Lawitz E., Marcellin P., Vierling J. M., Zeuzem S., Poordad F., Goodman Z. D., Sings H. L., Boparai N., Burroughs M., Brass C. A., Albrecht J. K., Esteban R., Boceprevir for previously treated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011 364 13 1207 1217 2-s2.0-79953176289 10.1056/NEJMoa1009482
29. Sitole M., Silva M., Spooner L., Comee M. K., Malloy M., Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clinical Therapeutics 2013 35 2 190 197 10.1016/j.clinthera. 2012.12.017
30. Asselah T., Marcellin P., Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver International 2012 32 supplement 1 88 102 10.1111/j.1478-3231.2011.02699.x
31. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A. M., Young S. K., Lee B., Heckerman D., Carlson J., Reyor L. L., Kleyman M., McMahon C. M., Birch C., zur Wiesch J. S., Ledlie T., Koehrsen M., Kodira C., Roberts A. D., Lauer G. M., Rosen H. R., Bihl F., Cerny A., Spengler U., Liu Z., Kim A. Y., Xing Y., Schneidewind A., Madey M. A., Fleckenstein J. F., Park V. M., Galagan J. E., Nusbaum C., Walker B. D., Lake-Bakaar G. V., Daar E. S., Jacobson I. M., Gomperts E. D., Edlin B. R., Donfield S. M., Chung R. T., Talal A. H., Marion T., Birren B. W., Henn M. R., Allen T. M., Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008 48 6 1769 1778 2-s2.0-58149388300 10.1002/hep.22549
32. Hofmann W. P., Herrmann E., Sarrazin C., Zeuzem S., Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver International 2008 28 10 1332 1343 2-s2.0-54049097126 10.1111/j.1478-3231. 2008.01896.x
33. Thomas E., Feld J. J., Li Q., Hu Z., Fried M. W., Liang T. J., Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011 53 1 32 41 2-s2.0-78751545582 10.1002/hep.23985
34. McHutchison J. G., Manns M. P., Muir A. J., Terrault N. A., Jacobson I. M., Afdhal N. H., Heathcote E. J., Zeuzem S., Reesink H. W., Garg J., Bsharat M., George S., Kauffman R. S., Adda N., Di Bisceglie A. M., Telaprevir for previously treated chronic HCV infection. The New England Journal of Medicine 2010 362 14 1292 1303 2-s2.0-77950817619 10.1056/NEJMoa0908014
35. Poordad F., Lawitz E., Shiffman M. L., Hassanein T., Muir A. J., Bacon B. R., Heise J., Halliman D., Chun E., Hammond J., Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010 52 4 1208 1215 2-s2.0-77957937673 10.1002/hep.23827
36. Marcellin P., Gish R. G., Gitlin N., Heise J., Halliman D. G., Chun E., Rodriguez-Torres M., Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. Journal of Hepatology 2010 52 1 32 38 2-s2.0-71149099686 10.1016/j.jhep.2009.10. 015
37. Zeuzem S., Buggisch P., Agarwal K., The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012 55 3 749 758 10.1002/hep.24744
38. Gane E. J., Stedman C. A., Hyland R. H., Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. The New England Journal of Medicine 2013 368 1 34 44 10.1056/NEJMoa1208953
39. Nelson D. R., Gane E. J., Jacobson I. M., di Bisceglie A. M., Alves K., Koziel M. J., VX-222/telaprevir in combination with peginterferon-alpha-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Hepatology 2011 54 1435. abstract LB-14
40. Zeuzem S., Arora S., Bacon B., Pegylated interferon-lambda (PegIFN- ) shows superior viral response with improved safety and tolerability versus pegIFN-a-2a in HCV patients, (G1/2/3/4): EMERGE phase IIb through week 12. Proceedings of the 46th Annual Meeting of the European Association for the Study of the Liver (EASL '11) April 2011 Berlin, Germany. http://www.natap.org/2011/ EASL/EASL-29.htm
41. Friborg J., Levine S., Chen C., Sheaffer A. K., Chaniewski S., McPhee F., Combination of interferon lambda with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother 2013 57 3 1312 1322 10.1128/AAC.02239-12
42. Malmgaard L., Induction and regulation of IFNs during viral infections. Journal of Interferon and Cytokine Research 2004 24 8 439 454 2-s2.0-4344658402 10.1089/1079990041689665 (Pubitemid 39120592)
43. Kieffer T. L., Sarrazin C., Miller J. S., Welker M. W., Forestier N., Reesink H. W., Kwong A. D., Zeuzem S., Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007 46 3 631 639 2-s2.0-34548758435 10.1002/hep.21781 (Pubitemid 47436107)
44. Sarrazin C., Hézode C., Zeuzem S., Pawlotsky J. M., Antiviral strategies in hepatitis C virus infection. Journal of Hepatology 2012 56 supplement 1 S88 S100
45. Sarrazin C., Zeuzem S., Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010 138 2 447 462 2-s2.0-75149151884 10.1053/j.gastro.2009.11.055
46. Gane E. J., Roberts S. K., Stedman C. A. M., Angus P. W., Ritchie B., Elston R., Ipe D., Morcos P. N., Baher L., Najera I., Chu T., Lopatin U., Berrey M. M., Bradford W., Laughlin M., Shulman N. S., Smith P. F., Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. The Lancet 2010 376 9751 1467 1475 2-s2.0-78049527728 10.1016/S0140-6736(10)61384-0
47. McCown M., Rajyaguru S., Kular S., Cammack N., Najera I., Suppression of in vitro resistance development after treatment of the HCV replicon with NS3/4a inhibitor ITMN-191 (R7227) in combination with nucleoside inhibitor R7128 or R1626. Journal of Hepatology 2009 50 S349
48. Zeuzem S., Asselah T., Angus P., Efficacy of the protease inhibitor BI, 201335, polymerase inhibitor BI, 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011 141 6 2047 2055 10.1053/j.gastro.2011.08. 051
49. Lok A. S., Gardiner D. F., Lawitz E., Preliminary study of two antiviral agents for hepatitis C genotype 1. The New England Journal of Medicine 2012 366 3 216 224 10.1056/NEJMoa1104430
50. McPhee F., Sheaffer A. K., Friborg J., Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrobial Agents and Chemotherapy 2012 56 10 5387 5396 10.1128/AAC.01186-12
51. Chayama K., Takahashi S., Toyota J., Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null-responders. Hepatology 2012 55 3 742 748 10.1002/hep.24724
52. Suzuki Y., Ikeda K., Suzuki F., Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Journal of Hepatology 2012 10.1016/j.jhep.2012.09.037
53. Lawitz E., Rodriguez-Torres M., Denning J., Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at Day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). Journal of Hepatology 2011 54 supplement 1 S543. abstract 1370
54. Sulkowski M., Gardiner D., Lawitz E., Potent viral suppression with the alloralcombination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/-, ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver April 2012 Barcelona, Spain
55. Gilead Sciences, Gilead announces early sustained virologic response rates for GS-7977 plus ribavirin in genotype 1 treatment-naive hepatitis C patients: interim results reported from ELECTRON and QUANTUM studies. 2012, http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID= 1684792&highlight
56. Poordad F., Lawitz E., Kowdley K. V., Exploratory study of oral combination antiviral therapy for hepatitis C. The New England Journal of Medicine 2013 368 1 45 53 10.1056/NEJMoa1208809
57. Sulkowski M. S., Moore R. D., Mehta S. H., Chaisson R. E., Thomas D. L., Hepatitis C and progression of HIV disease. Journal of the American Medical Association 2002 288 2 199 206 2-s2.0-0037055011 (Pubitemid 34755280)
58. Soriano V., Labarga P., Ruiz-Sancho A., Garcia-Samaniego J., Barreiro P., Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 2006 20 17 2225 2227 2-s2.0-33750586572 10.1097/01.aids.0000247583.38943.95
59. Berenguer J., Rodríguez E., Miralles P., Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clinical Infectious Diseases 2012 55 5 728 736 10.1093/cid/cis500
60. Dieterich D., Soriano V., Shermann K., Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: 24-week treatment interim analysis. March 2012 Seattle Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections (CROI '12). abstract 46
61. Mallolas J., Pol S., Rivero A., Boceprevir plus peginterferon/ribavirin for the treatment of HIV-HCVcoinfected patients: end of treatment week 48 interim results. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver (EASL '12) April 2012 Barcelona, Spain. abstract 366
62. Rodríguez-Torres M., Focus on drug interactions: the challenge of treating hepatitis C virus infection with directacting antiviral drugs in the HIV-positive patient. Current Opinion in Infectious Diseases 2013 26 1 50 57
63. Wartelle-Bladou C., le Folgoc G., Bourlière M., Lecomte L., Hepatitis C therapy in non-genotype 1 patients: the near future. Journal of Viral Hepatitis 2012 19 8 525 536
64. Foster G. R., Hézode C., Bronowicki J. P., Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011 141 3 881 889 10.1053/j.gastro.2011.05.046
65. Benhamou Y., Moussalli J., Ratziu V., Activity of telaprevir or in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 hepatitis C patients. Final results of study C210. Hepatology 2010 52 719A 720A
66. Lin T. I., Lenz O., Fanning G., Verbinnen T., Delouvroy F., Scholliers A., Vermeiren K., Rosenquist Â., Edlund M., Samuelsson B., Vrang L., De Kock H., Wigerinck P., Raboisson P., Simmen K., In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitory. Antimicrobial Agents and Chemotherapy 2009 53 4 1377 1385 2-s2.0-65749112245 10.1128/AAC.01058-08
67. Moreno C., Berg T., Tanwandee T., Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. Journal of Hepatology 2012 56 6 1247 1253 10.1016/j.jhep.2011.12.033
68. Gottwein J. M., Scheel T. K., Jensen T. B., Ghanem L., Bukh J., Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011 141 3 1067 1079 10.1053/j.gastro.2011.06.004
69. Everson G., Cooper C., Hezode C., Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/PEGIFN alfa-2A/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis. Journal of Hepatology 2012 56 S466